Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Advances in Respiratory Medicine
MENU
Shortcuts Submit an article Guide for Authors Ahead Of Print Author statement Editorial Policy and Information for Authors Reviewers 2020

open access

Vol 77, No 1 (2009)
Review paper
Published online: 2008-12-19
Submitted: 2013-02-22
View PDF (polish) Download PDF file
Get Citation

Omalizumab, recombinant humanized monoclonal antibody anti-IgE - new fields of studies on the therapeutic indications

Izabela Kupryś-Lipińska, Piotr Kuna
Pneumonol Alergol Pol 2009;77(1):43-51.

open access

Vol 77, No 1 (2009)
REVIEWS
Published online: 2008-12-19
Submitted: 2013-02-22

Abstract

Omalizumab is the monoclonal antibody against IgE, which blocks the binding of IgE to receptors on effector cells and this way blocks or decreases allergic reaction and asthma symptoms. Nowadays omalizumab is registered in the USA and European Union including Poland for treatment of patients with severe persistent, uncontrolled asthma. It is very effective in the reduction of asthma exacerbations, hospitalizations and emergency visits, it decreases intensity of symptoms and improves the quality of life. But omalizumab has more extensive action; given subcutaneously it has systemic effect. The article is the review of the studies and case reports on usage of omalizumab in new indications. Some authors’ own experiences in this field are also presented.

Abstract

Omalizumab is the monoclonal antibody against IgE, which blocks the binding of IgE to receptors on effector cells and this way blocks or decreases allergic reaction and asthma symptoms. Nowadays omalizumab is registered in the USA and European Union including Poland for treatment of patients with severe persistent, uncontrolled asthma. It is very effective in the reduction of asthma exacerbations, hospitalizations and emergency visits, it decreases intensity of symptoms and improves the quality of life. But omalizumab has more extensive action; given subcutaneously it has systemic effect. The article is the review of the studies and case reports on usage of omalizumab in new indications. Some authors’ own experiences in this field are also presented.

Full Text:

View PDF (polish) Download PDF file
Get Citation

Keywords

omalizumab; atopic diseases; allergic rhinitis; atopic dermatitis; urticaria

About this article
Title

Omalizumab, recombinant humanized monoclonal antibody anti-IgE - new fields of studies on the therapeutic indications

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 1 (2009)

Article type

Review paper

Pages

43-51

Published online

2008-12-19

Bibliographic record

Pneumonol Alergol Pol 2009;77(1):43-51.

Keywords

omalizumab
atopic diseases
allergic rhinitis
atopic dermatitis
urticaria

Authors

Izabela Kupryś-Lipińska
Piotr Kuna

References (55)
  1. Kupryś I, Kuna P. [Regulation of immunoglobulin E synthesis]. Postepy Hig Med Dosw. 1997; 51(6): 651–682.
    PubMed
  2. Bozelka BE, McCants ML, Salvaggio JE, et al. IgE isotype suppression in anti-epsilon-treated mice. Immunology. 1982; 46(3): 527–532.
    PubMed
  3. Hamelmann E. The rationale for treating allergic asthma with anti-IgE. European Respiratory Review. 2007; 16(104): 61–66.
    CrossRef
  4. Bobrowska M, Stelmach I. [Therapeutic possibilities and clinical effects of IgE level modulation in allergic diseases]. Pneumonol Alergol Pol. 2004; 72(1-2): 70–74.
    PubMed
  5. Sarinho E, Cruz AA. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases. J Pediatr (Rio J). 2006; 82(5 Suppl): S127–S132.
    CrossRefPubMed
  6. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170(6): 583–593.
    CrossRefPubMed
  7. MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158(3): 1438–1445.
    PubMed
  8. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004; 113(2): 297–302.
    CrossRefPubMed
  9. Chang TW, Shiung YY. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol. 2006; 117(6): 1203–1212.
    CrossRefPubMed
  10. Saini SS, MacGlashan DW, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999; 162(9): 5624–5630.
    PubMed
  11. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003; 112(6): 1147–1154.
    CrossRefPubMed
  12. Noga O, Hanf G, Kunkel G, et al. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol. 2008; 146(1): 66–70.
    CrossRefPubMed
  13. Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006; 117(6): 1493–1499.
    CrossRefPubMed
  14. Charakterystyka produktu leczniczego Xolair. www.novartis.pl.
  15. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60(3): 302–308.
    CrossRefPubMed
  16. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2004(3): CD003559.
    CrossRefPubMed
  17. Chipps B, Buhl R, Beeh KM, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006; 22(11): 2201–2208.
    CrossRefPubMed
  18. Casale TB, Condemi J, LaForce C, et al. Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001; 286(23): 2956–2967.
    PubMed
  19. Ogino S, Nagakura T, Okubo K, et al. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006; 55(4): 379–386.
    CrossRefPubMed
  20. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003; 91(2): 160–167.
    CrossRefPubMed
  21. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004; 59(7): 709–717.
    CrossRefPubMed
  22. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005; 53(2): 338–340.
    CrossRefPubMed
  23. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006; 54(1): 68–72.
    CrossRefPubMed
  24. Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006; 55(1): 168–170.
    CrossRefPubMed
  25. Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis. 2007; 80(1): 38–40.
    PubMed
  26. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007; 120(5): 1223–1225.
    CrossRefPubMed
  27. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007; 99(2): 190–193.
    CrossRefPubMed
  28. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006; 117(6): 1415–1418.
    CrossRefPubMed
  29. Metz M, Bergmann P, Zuberbier T, et al. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008; 63(2): 247–249.
    CrossRefPubMed
  30. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007; 120(4): 979–981.
    CrossRefPubMed
  31. Leung DYM, Sampson HA, Yunginger JW, et al. Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003; 348(11): 986–993.
    CrossRefPubMed
  32. Chang TW, Wu PC, Hsu CL, et al. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol. 2007; 93: 63–119.
    CrossRefPubMed
  33. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol. 2004; 113(2): 360–361.
    PubMed
  34. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax. 2007; 62(3): 276–277.
    CrossRefPubMed
  35. Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007; 119(6): 1550–1551.
    CrossRefPubMed
  36. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, et al. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007; 144(2): 155–158.
    CrossRefPubMed
  37. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med. 2006; 355(12): 1281–1282.
    CrossRefPubMed
  38. Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008; 121(1): 253–254.
    CrossRefPubMed
  39. Bargagli E, Madioni C, Olivieri C, et al. Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma. 2008; 45(2): 115–116.
    CrossRefPubMed
  40. Lee J, Doggweiler-Wiygul R, Kim S, et al. Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE. Int J Urol. 2006; 13(5): 631–634.
    CrossRefPubMed
  41. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109(2): 274–280.
    PubMed
  42. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. Omalizumab Rhinitis Study Group. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004; 59(9): 973–979.
    CrossRefPubMed
  43. Kopp MV, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 110(5): 728–735.
    PubMed
  44. Kopp MV, Mayatepek E, Engels E, et al. Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). Pediatr Allergy Immunol. 2003; 14(5): 401–404.
    PubMed
  45. Bez C, Schubert R, Kopp M, et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2004; 34(7): 1079–1085.
    CrossRefPubMed
  46. Kopp MV, Stenglein S, Kamin W, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol. 2007; 18(6): 523–527.
    CrossRefPubMed
  47. Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006; 117(1): 134–140.
    CrossRefPubMed
  48. Klunker S, Saggar LR, Seyfert-Margolis V, et al. Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007; 120(3): 688–695.
    CrossRefPubMed
  49. Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy. 2007; 62(8): 963–964.
    CrossRefPubMed
  50. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008; 63(3): 376–378.
    CrossRefPubMed
  51. Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol. 2008; 18(3): 225–226.
    PubMed
  52. Limb SL, Starke PR, Lee CE, et al. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007; 120(6): 1378–1381.
    CrossRefPubMed
  53. Cox L, Platts-Mills TAE, Finegold I, et al. American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007; 120(6): 1373–1377.
    CrossRefPubMed
  54. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006; 96(4): 624–627.
    CrossRefPubMed
  55. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007; 28(3): 313–319.
    PubMed

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl